Association of Opioid and Stimulant Use Disorder Diagnoses With Fatal and Nonfatal Overdose Among People With a History of Incarceration.

Heather Palis, Wenqi Gan, Chloe Xavier, Roshni Desai, Marnie Scow, Kali-Olt Sedgemore, Leigh Greiner, Tonia Nicholls, Amanda Slaunwhite
Author Information
  1. Heather Palis: BC Centre for Disease Control, Vancouver, British Columbia, Canada.
  2. Wenqi Gan: BC Centre for Disease Control, Vancouver, British Columbia, Canada.
  3. Chloe Xavier: BC Centre for Disease Control, Vancouver, British Columbia, Canada.
  4. Roshni Desai: BC Centre for Disease Control, Vancouver, British Columbia, Canada.
  5. Marnie Scow: BC Centre for Disease Control, Vancouver, British Columbia, Canada.
  6. Kali-Olt Sedgemore: BC Centre for Disease Control, Vancouver, British Columbia, Canada.
  7. Leigh Greiner: BC Corrections, Victoria, British Columbia, Canada.
  8. Tonia Nicholls: Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
  9. Amanda Slaunwhite: BC Centre for Disease Control, Vancouver, British Columbia, Canada.

Abstract

Importance: Studies have suggested a rise in opioid- and stimulant-involved overdoses in recent years in North America. This risk may be acute for individuals who have had contact with the criminal justice system, who are particularly vulnerable to overdose risk.
Objective: To examine the association of opioid and/or stimulant use disorder diagnoses with overdose (fatal and nonfatal) among people with histories of incarceration.
Design, Setting, and Participants: In this cohort study, population-based health and corrections data were retrieved from the British Columbia Provincial overdose Cohort, which contains a 20% random sample of residents of British Columbia. The analysis included all people in the 20% random sample who had a history of incarceration between January 1, 2010, and December 31, 2014. Outcomes were derived from 5-years of follow-up data (January 1, 2015, to December 31, 2019). Statistical analysis took place from January 2022 to June 2022.
Exposures: Substance use disorder diagnosis type (ie, opioid use disorder, stimulant use disorder, both, or neither), sociodemographic, health, and incarceration characteristics.
Main Outcomes and Measures: Hazard ratios (HRs) are reported from an Andersen-Gill model for recurrent nonfatal overdose events and from a Fine and Gray competing risk model for fatal overdose events.
Results: The study identified 6816 people (5980 male [87.7%]; 2820 aged <30 years [41.4%]) with histories of incarceration. Of these, 293 (4.3%) had opioid use disorder only, 395 (6.8%) had stimulant use disorder only, and 281 (4.1%) had both diagnoses. During follow-up, 1655 people experienced 4026 overdoses including 3781 (93.9%) nonfatal overdoses, and 245 (6.1%) fatal overdoses. In adjusted analyses, the hazard of both fatal (HR, 2.39; 95% CI, 1.48-3.86) and nonfatal (HR, 2.45; 95% CI, 1.94-3.11) overdose was highest in the group with both Opioid and stimulant use disorder diagnoses.
Conclusions and Relevance: This cohort study of people with a history of incarceration found an elevated hazard of fatal and nonfatal overdose among people with both Opioid and stimulant use disorder diagnoses. This study suggests an urgent need to address the service needs of individuals who have had contact with the criminal justice system and who co-use opioids and stimulants.

References

  1. Subst Abuse. 2021 Jun 17;15:1178221820976988 [PMID: 34211275]
  2. J Glob Health. 2021 Feb 11;11:04009 [PMID: 33692893]
  3. JACC Heart Fail. 2019 Sep;7(9):771-778 [PMID: 31466673]
  4. Harm Reduct J. 2022 May 19;19(1):46 [PMID: 35590375]
  5. Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255 [PMID: 32601988]
  6. CMAJ Open. 2020 Feb 18;8(1):E1-E8 [PMID: 32071141]
  7. JAMA Netw Open. 2018 Jul 6;1(3):e180558 [PMID: 30646016]
  8. Subst Use Misuse. 2020;55(13):2165-2174 [PMID: 32686551]
  9. Am J Med. 2019 Apr;132(4):478-488.e4 [PMID: 30562497]
  10. Drug Alcohol Depend. 2007 Feb 23;87(1):20-9 [PMID: 16930863]
  11. CMAJ. 2022 Jan 31;194(4):E127-E128 [PMID: 35101873]
  12. Med Care. 1998 Jan;36(1):8-27 [PMID: 9431328]
  13. Drug Alcohol Depend. 2018 Dec 1;193:14-20 [PMID: 30326396]
  14. Harm Reduct J. 2021 May 20;18(1):57 [PMID: 34016137]
  15. PLoS One. 2019 Jan 10;14(1):e0210129 [PMID: 30629607]
  16. Addiction. 2021 Jun;116(6):1460-1471 [PMID: 33047844]
  17. Addiction. 2022 Jan;117(1):129-140 [PMID: 34033179]
  18. Subst Abuse Treat Prev Policy. 2021 Sep 16;16(1):68 [PMID: 34530878]
  19. Addiction. 2020 Sep;115(9):1683-1694 [PMID: 32096302]
  20. Clin Res Cardiol. 2021 Oct 15;: [PMID: 34654963]
  21. Emerg Radiol. 2012 Apr;19(2):165-73 [PMID: 22237695]
  22. Lancet. 2016 May 28;387(10034):2226-34 [PMID: 27015909]
  23. Cardiol Res Pract. 2020 May 08;2020:1985379 [PMID: 32454995]
  24. Addiction. 2019 Jan;114(1):103-111 [PMID: 30209840]
  25. Lancet Public Health. 2021 Apr;6(4):e249-e259 [PMID: 33773635]
  26. Int J Drug Policy. 2017 Oct;48:1-8 [PMID: 28666202]
  27. J Gen Intern Med. 2022 Oct;37(13):3462-3464 [PMID: 35713806]
  28. Addiction. 2014 Mar;109(3):440-9 [PMID: 24118269]
  29. Addiction. 2003 Aug;98(8):1169-71 [PMID: 12873254]
  30. Drug Alcohol Depend. 2021 Feb 1;219:108435 [PMID: 33310383]
  31. Eur Addict Res. 2018;24(1):43-51 [PMID: 29510390]
  32. Psychol Med. 2015 Jan;45(2):247-58 [PMID: 25066071]
  33. Addiction. 2010 Sep;105(9):1545-54 [PMID: 20579009]
  34. Drug Alcohol Depend. 2021 Aug 1;225:108830 [PMID: 34182376]
  35. Drug Alcohol Rev. 2022 May;41(4):912-917 [PMID: 34908203]
  36. JAMA Netw Open. 2021 Oct 1;4(10):e2130795 [PMID: 34694389]
  37. Curr Pharm Des. 2015;21(23):3359-66 [PMID: 26088112]
  38. Drug Alcohol Depend. 2021 Sep 1;226:108838 [PMID: 34271512]
  39. Psychiatr Serv. 2022 Jul;73(7):737-744 [PMID: 34809437]
  40. Subst Abuse Treat Prev Policy. 2021 Feb 15;16(1):17 [PMID: 33588896]
  41. Addiction. 2020 May;115(5):917-923 [PMID: 31908066]
  42. CMAJ. 2018 Mar 5;190(9):E247-E257 [PMID: 29507156]
  43. J Clin Psychiatry. 2007 Jul;68(7):e18 [PMID: 17685729]
  44. JAMA Psychiatry. 2021 Oct 1;78(10):1092-1102 [PMID: 34347030]
  45. J Addict Med. 2012 Jun;6(2):97-105 [PMID: 22134174]

Grants

  1. /CIHR

MeSH Term

Male
Humans
Analgesics, Opioid
Cohort Studies
Drug Overdose
Opioid-Related Disorders
Central Nervous System Stimulants

Chemicals

Analgesics, Opioid
Central Nervous System Stimulants

Word Cloud

Created with Highcharts 10.0.0usedisorderoverdosepeopleopioidstimulantfatalnonfatalincarcerationoverdosesdiagnosesstudy1riskJanuaryyearsindividualscontactcriminaljusticesystemamonghistoriescohorthealthdataBritishColumbiaOverdose20%randomsampleanalysishistoryDecember31Outcomesfollow-up2022modelevents461%hazardHR295%CIImportance:Studiessuggestedriseopioid-stimulant-involvedrecentNorthAmericamayacuteparticularlyvulnerableObjective:examineassociationand/orDesignSettingParticipants:population-basedcorrectionsretrievedProvincialCohortcontainsresidentsincluded20102014derived5-years20152019StatisticaltookplaceJuneExposures:SubstancediagnosistypeieneithersociodemographiccharacteristicsMainMeasures:HazardratiosHRsreportedAndersen-GillrecurrentFineGraycompetingResults:identified68165980male[877%]2820aged<30[414%]2933%3958%2811655experienced4026including3781939%245adjustedanalyses3948-3864594-311highestgroupConclusionsRelevance:foundelevatedsuggestsurgentneedaddressserviceneedsco-useopioidsstimulantsAssociationOpioidStimulantUseDisorderDiagnosesFatalNonfatalAmongPeopleHistoryIncarceration

Similar Articles

Cited By